J. P. Benya
Chief Operating Officer at Flame Biosciences LLC
Profile
J.
P.
Benya is a Senior Vice President-Operations at Flame Biosciences LLC.
Previously, he worked as a Marketing Director at Schering-Plough Corp., Managing Director & Head-Overseas Marketing at Mezzion Pharma Co., Ltd., Vice President-Marketing & Business Development at Transcept Pharmaceuticals, Inc. (Old), and VP-Commercial Operations & Business Development at Ventrus Biosciences, Inc. He also served as Vice President-Business Development at Assembly Biosciences, Inc. from 2015 to 2019.
Mr. Benya completed his undergraduate degree at Brown University and earned an MBA from The Trustees of Columbia University in The City of New York.
J. P. Benya active positions
Companies | Position | Start |
---|---|---|
Flame Biosciences LLC
Flame Biosciences LLC Miscellaneous Commercial ServicesCommercial Services Flame Biosciences, Inc. operates as a biotechnology company. The firm offers research, development and commercialization of transformative therapies for cancer and other inflammatory conditions. The company was founded by Charles J. Fisher Jr., Patrick J. Scannon and Bob Stein and is headquartered in New York, NY. | Chief Operating Officer | - |
Former positions of J. P. Benya
Companies | Position | End |
---|---|---|
ASSEMBLY BIOSCIENCES, INC. | Corporate Officer/Principal | 2019-11-30 |
Transcept Pharmaceuticals, Inc. (Old)
Transcept Pharmaceuticals, Inc. (Old) Pharmaceuticals: MajorHealth Technology Transcept Pharmaceuticals, Inc. researches and develops biopharmaceutical products. The firm's products are used for pain, side effects of chemotherapy treatments, sleeplessness, and migraine headaches. Its drug delivery technology enhances absorption rates of active drug agents reduces absorption times. The company was founded in January, 2002 by Nikhilesh Singh and is headquartered in Pt. Richmond, CA. | Sales & Marketing | 2009-02-02 |
MEZZION PHARMA CO.,LTD. | Sales & Marketing | - |
Ventrus Biosciences, Inc.
Ventrus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ventrus Biosciences, Inc. is a development stage specialty pharmaceutical company engages in development of late-stage prescription drugs for gastrointestinal disorders, specifically hemorrhoidal disease, anal fissures, and fecal incontinence. Its major pharmaceutical progress made in the gastrointestinal therapeutic areas of gastroesophageal reflux, peptic ulcer disease, and inflammatory bowel disease. Ventrus Biosciences products includes VEN 307 (topical diltiazem), is intended to treat pain associated with anal fissures and VEN 308 (topical phenylephrine), is intended to treat fecal incontinence. The company was founded on October 10, 2005 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Sales & Marketing | - |
Training of J. P. Benya
Brown University | Undergraduate Degree |
The Trustees of Columbia University in The City of New York | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
MEZZION PHARMA CO.,LTD. | Health Technology |
ASSEMBLY BIOSCIENCES, INC. | Health Technology |
Private companies | 4 |
---|---|
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Health Technology |
Transcept Pharmaceuticals, Inc. (Old)
Transcept Pharmaceuticals, Inc. (Old) Pharmaceuticals: MajorHealth Technology Transcept Pharmaceuticals, Inc. researches and develops biopharmaceutical products. The firm's products are used for pain, side effects of chemotherapy treatments, sleeplessness, and migraine headaches. Its drug delivery technology enhances absorption rates of active drug agents reduces absorption times. The company was founded in January, 2002 by Nikhilesh Singh and is headquartered in Pt. Richmond, CA. | Health Technology |
Ventrus Biosciences, Inc.
Ventrus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ventrus Biosciences, Inc. is a development stage specialty pharmaceutical company engages in development of late-stage prescription drugs for gastrointestinal disorders, specifically hemorrhoidal disease, anal fissures, and fecal incontinence. Its major pharmaceutical progress made in the gastrointestinal therapeutic areas of gastroesophageal reflux, peptic ulcer disease, and inflammatory bowel disease. Ventrus Biosciences products includes VEN 307 (topical diltiazem), is intended to treat pain associated with anal fissures and VEN 308 (topical phenylephrine), is intended to treat fecal incontinence. The company was founded on October 10, 2005 and is headquartered in New York, NY. | Health Technology |
Flame Biosciences LLC
Flame Biosciences LLC Miscellaneous Commercial ServicesCommercial Services Flame Biosciences, Inc. operates as a biotechnology company. The firm offers research, development and commercialization of transformative therapies for cancer and other inflammatory conditions. The company was founded by Charles J. Fisher Jr., Patrick J. Scannon and Bob Stein and is headquartered in New York, NY. | Commercial Services |
- Stock Market
- Insiders
- J. P. Benya